NEW YORK —Euformatics has partnered with Bio.logis to combine their respective informatics technologies to provide pharmacogenomic information for patients undergoing next-generation sequencing-based genetic testing, the companies said on Tuesday.
Helsinki-based Euformatics markets tools for genomic data quality management and interpretation including its OmnomicsNGS annotation and variant interpretation platform. Bio.logis' primary offering is its Genetic Information Management Suite (GIMS), which analyzes and interprets raw data from genetic tests to generate diagnostic reports and provide treatment recommendations.
Under the terms of the deal, GIMS will be integrated into OmnomicsNGS so that pharmacogenomic results can be included with the platform's disease-related NGS variant analysis, clinical assessment, and reporting.
Additional terms were not disclosed.
"If labs are sequencing patients for diagnostic purposes, the genetic data is already there," Daniela Steinberger, CEO of Frankfurt, Germany-based Bio.logis, said in a statement. "Offering patients personalized dosing recommendations for hundreds of drugs … will help to increase efficacy of drugs taken and reduce side effects."